EpiCept Corporation recently announced operating and financial results for the year 2010, and provided an update on its key business initiatives.
Browsing: Jack Talley
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.